B of A Securities Maintains Buy on Keros Therapeutics, Lowers Price Target to $76
Portfolio Pulse from Benzinga Newsdesk
B of A Securities has maintained a Buy rating on Keros Therapeutics but lowered the price target from $81 to $76.
September 12, 2024 | 5:47 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
B of A Securities has maintained a Buy rating on Keros Therapeutics, indicating continued confidence in the company's prospects. However, the price target has been lowered from $81 to $76, suggesting a more conservative outlook on the stock's potential upside.
The maintenance of a Buy rating suggests that the analyst still sees potential in Keros Therapeutics, which is positive. However, the reduction in the price target indicates a tempered expectation of the stock's future performance, balancing the overall impact to neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100